Avenue Therapeutics received a deficiency letter from Nasdaq for not meeting the minimum stockholders equity requirement and bid price requirement, and is now at risk of being delisted.
AI Assistant
AVENUE THERAPEUTICS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.